Dark

ALBO
Albireo Pharma, Inc. Common Stock
stock NASDAQ

Inactive

Mar 2, 2023

44.15USD-0.226%(-0.10)1,241,282

Pre-market

Dec 31, 1969 7:00:00 PM EST

0.00USD-100.000%(-44.25)0

After-hours

Dec 31, 1969 7:00:00 PM EST

0.00USD0.000%(0.00)0

OverviewHistoricalExchangesShortsNews

Jan 5, 2022

09:00AM EST Albireo Increases 2021 GlobeNewswire Inc

08:53AM EST Albireo Announces BOLD Phase 3 Study Is Over 50% Enrolled, ASSERT Phase 3 Study On Track For Topline Data By End Of Year Benzinga

08:52AM EST Albireo Pharma Raises 2021 Bylvay Net Sales Guidance From $3M-$4M To $6M-$7M Benzinga

Dec 17, 2021

05:06PM EST 17:05 Friday, December 17, 2021Wedbush (RTTNews) - Wedbush Reiterates Albireo Pharma, Inc. (ALBO) At Outperform With $84 Price Target RTTNews

Dec 16, 2021

08:37AM EST Albireo Announces Topline Data From Phase 1 Study Of A3907; Says Study Achieved Both Primary And Secondary Objectives, Was Safe And Well Tolerated Benzinga

08:30AM EST Albireo Announces Positive Topline Data from Phase 1 Study of A3907 GlobeNewswire Inc

Dec 13, 2021

08:35AM EST Albireo To Present Posters At NASPGHAN 2021 Dec. 13 And 15 Benzinga

08:30AM EST Data show significant correlations in serum bile acid reductions and long-term improvements in pruritus and sleep GlobeNewswire Inc

Dec 9, 2021

09:00AM EST Albireo Announces Changes to R&D Organization GlobeNewswire Inc

Dec 2, 2021

08:30AM EST Albireo Expands Leadership with Constantine Chinoporos as Chief GlobeNewswire Inc

Nov 12, 2021

08:18AM EST Candel Therapeutics, Cue, Madrigal Pharma, F-star, Aligos, Albireo Pharma, Actinium Highlights Presentations At Society For Immunotherapy Of Cancers Meeting Nov. 12-14, The Liver Meeting Benzinga

08:14AM EST Candel Therapeutics, Cue, Madrigal Pharma, Aligos, Albireo Pharma, Actinium Highlights Presentations At Society For Immunotherapy Of Cancers Meeting Nov. 12-14, The Liver Meeting Benzinga

08:00AM EST Evidence of long-term clinical treatment benefit of Bylvay(odevixibat) showing improved liver health and function across PFIC types GlobeNewswire Inc

Nov 10, 2021

08:30AM EST Albireo Pharma, Inc. (Nasdaq: ALBO), a rare liver disease company developing novel bile acid modulators, today announced that Ron Cooper, President and Chief Executive Officer, Simon Harford, Chief Financial Officer and other members of the Companys management team will be presenting at the following investor conferences: GlobeNewswire Inc

Nov 5, 2021

12:43PM EDT HC Wainwright & Co. Maintains Buy on Albireo Pharma, Raises Price Target to $80 Benzinga

Nov 4, 2021

09:08AM EDT Albireo Pharma Q3 EPS $(2.03) Misses $(0.38) Estimate, Sales $3.66M Beat $3.48M Estimate Benzinga

05:00AM EDT Earnings Scheduled For November 4, 2021 Benzinga

Oct 28, 2021

08:30AM EDT Albireo Pharma, Inc. (Nasdaq: ALBO), a rare liver disease company developing novel bile acid modulators, today announced that management will host a conference call and live audio webcast at10:00 a.m. ET onNovember 4, 2021, to provide a business update and review the companys financial results for the third quarter ended September 30, 2021. GlobeNewswire Inc

Oct 15, 2021

08:35AM EDT Albireo To Showcase New Data At AASLD The Liver Meeting On Nov. 16 Benzinga

08:30AM EDT Seven abstracts accepted highlighting data in pediatric cholestatic and viral liver diseases GlobeNewswire Inc

Oct 12, 2021

08:38AM EDT Albireo Announces Exclusive Licensing Agreement With Jadeite Medicines For Bylvay In Japan; Albireo To Receive Upfront Payment Of $15 And Up To $120M In Milestones Benzinga

08:30AM EDT Agreement to accelerate commercialization of Bylvay(odevixibat)in Japan, a significant market for PFIC, Alagille syndrome and biliary atresia GlobeNewswire Inc

Oct 5, 2021

08:30AM EDT Albireo Recognizes PFIC Awareness Day 2021 GlobeNewswire Inc

Sep 16, 2021

08:55AM EDT Wedbush Maintains Outperform on Albireo Pharma, Raises Price Target to $84 Benzinga

Sep 15, 2021

08:34AM EDT Albireo Announces Bylvay (odevixibat) Now Available In Germany Benzinga

08:30AM EDT Listed on the German national price list and all pharmacy software programs GlobeNewswire Inc

Sep 8, 2021

04:30PM EDT Albireo Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) GlobeNewswire Inc

08:38AM EDT Albireo Pharma: MHRA Grants Marketing Authorization For Bylvay For Progressive Familial Intrahepatic Cholestasis RTTNews

08:30AM EDT Bylvay now approved in U.S., EU and UK as first drug treatment for patients with PFIC GlobeNewswire Inc

Sep 7, 2021

11:05AM EDT Albireo Pharma Sells Bylvay-Associated PRV For $105M Benzinga

08:37AM EDT Albireo Sells Priority Review Voucher For $105M Benzinga

08:30AM EDT PRV was granted to Albireo with the FDA approval of BylvayTM (odevixibat) in July GlobeNewswire Inc

Sep 2, 2021

08:30AM EDT Albireo Pharma, Inc. (Nasdaq: ALBO), a rare pediatric liver disease company developing novel bile acid modulators, today announced that Ron Cooper, President and Chief Executive Officer, Simon Harford, Chief Financial Officer and other members of the Companys management team will be presenting at the following investor conferences: GlobeNewswire Inc

Aug 27, 2021

05:12PM EDT Looking into Albireo Pharma's Return on Capital Employed Benzinga

Aug 5, 2021

08:47AM EDT Albireo Pharma Q2 EPS $(1.90) Beats $(1.96) Estimate, Sales $2.43M Beat $1.98M Estimate Benzinga

04:08AM EDT Earnings Scheduled For August 5, 2021 Benzinga

Aug 3, 2021

08:30AM EDT Albireo Pharma, Inc. (Nasdaq: ALBO), a rare liver disease company developing novel bile acid modulators, today announced thatRon Cooper, President and Chief Executive Officer and Simon Harford, Chief Financial Officer, will present at the 2021 Wedbush PacGrow Virtual Healthcare Conference on Tuesday, August 10, at3:30 p.m. ET. GlobeNewswire Inc

Aug 2, 2021

06:10PM EDT Attention Biotech Investors: Mark Your Calendar For August PDUFA Dates Benzinga

Jul 29, 2021

08:30AM EDT Albireo Pharma, Inc. (Nasdaq: ALBO), a rare liver disease company developing novel bile acid modulators, today announced that management will host a conference call and live audio webcast at10:00 a.m. ET onAugust 5, 2021, to provide a business update and review the companys financial results for the second quarter ended June 30, 2021. GlobeNewswire Inc

Jul 25, 2021

10:05AM EDT The Week Ahead In Biotech (July 25-31): Big Pharma Earnings, Iterum FDA Decision, Alzheimer's Conference, IPOs and More Benzinga

Jul 21, 2021

08:41AM EDT Wedbush Maintains Outperform on Albireo Pharma, Raises Price Target to $82 Benzinga

06:19AM EDT HC Wainwright & Co. Maintains Buy on Albireo Pharma, Raises Price Target to $79 Benzinga

06:10AM EDT Albireo's Rare Liver Disease Drug Bylvay Scores Back To Back Approvals In Europe, US Benzinga

Jul 20, 2021

05:21PM EDT MULTIMEDIA UPDATE - Albireo Announces FDA Approval of GlobeNewswire Inc

04:14PM EDT Albireo Pharma Issues PR Confirming FDA Approval For Co.'s Odevixibat Benzinga

04:00PM EDT Albireo Announces FDA Approval of Bylvay GlobeNewswire Inc

03:24PM EDT Albireo Pharma Shares Spike Higher As Traders Circulate FDA AccessData.gov Listing Showing FDA Approval For Co.'s Odevixibat Benzinga

08:20AM EDT The Daily Biotech Pulse: Ardelyx Sinks On Regulatory Setback, AnPac Issues Positive Preannouncement, European Nod For Myovant, HCW Biologics Debuts On Wall Street Benzinga

Jul 19, 2021

09:36AM EDT Albireo's Bylvay Scores European Nod For Rare Pediatric Liver Disease Benzinga

08:08AM EDT Albireo Receives European Marketing Authorization Of Bylvay For Progressive Familial Intrahepatic Cholestasis Benzinga

08:01AM EDT Albireo Receives European Marketing Authorization of GlobeNewswire Inc

Jul 8, 2021

08:33AM EDT Albireo Pharma, Inc. (Nasdaq: ALBO), a rare liver disease company developing novel bile acid modulators, today announced thatRon Cooper, President and Chief Executive Officer, will present at the William Blair Biotech Focus Conference on Thursday, July 15, at11:00 a.m. EDT. GlobeNewswire Inc

Jun 24, 2021

08:00AM EDT Albireo Pharma, Inc. (Nasdaq: ALBO), a rare liver disease company developing novel bile acid modulators, today announced thatRon Cooper, President and Chief Executive Officer, will present as part of a fireside chat at Piper Sandlers Virtual EASL Takeaway Day on Monday, June 28, at10:00 a.m. EDT. GlobeNewswire Inc

Jun 21, 2021

11:05AM EDT Albireo's Bylvay Shows Further Evidence Of Sustained, Durable Effect In Pediatric Liver Disease Study Benzinga

06:05AM EDT Albireo Announces Expanded Phase 3 Data on Bylvay and A3907 at Upcoming EASL International Liver Congress Benzinga

06:00AM EDT Bylvay demonstrates rapid reductions in serum bile acids and long-term improvements in growth, sleep, and hepatic parameters GlobeNewswire Inc

Jun 10, 2021

08:30AM EDT Phase 3 data presentations on long-term treatment and substantial clinical benefits of Bylvay(odevixibat) GlobeNewswire Inc

Jun 3, 2021

04:31PM EDT Albireo Pharma Highlights Presentation Of Data From Phase 3 PEDFIC Study Benzinga

04:30PM EDT Data being presented show long-term benefits of Bylvay in children with PFIC GlobeNewswire Inc

May 26, 2021

08:30AM EDT Albireo to Present at Upcoming Jefferies and William Blair Virtual GlobeNewswire Inc

May 21, 2021

12:48PM EDT Albireo's Bylvay Wins Positive Opinion from EMA For Rare Pediatric Liver Disease Benzinga

09:18AM EDT Albireo Pharma Inc. (ALBO) said that the European Medicines Agency's Committee for Medicinal Products for Human Use or CHMP issued a positive opinion recommending approval of Bylvay or odevixibat for the treatment of Progressive Familial Intrahepatic Cholestasis or PFIC. RTTNews

08:51AM EDT Albireo Pharma Receives Positive CHMP Opinion For Bylvay For Treatment Of PFIC RTTNews

08:36AM EDT Bylvay has the potential to become first approved drug to treat all forms of PFIC GlobeNewswire Inc

07:36AM EDT EMA Says Recommended Granting A Marketing Authorization In European Union For Albireo's Bylvay For Treatment Of PFIC In Patients Aged 6 Months Or Older Benzinga

May 19, 2021

08:30AM EDT - PEDFIC 1 and PEDFIC 2 Phase 3 data presentations on long-term safety, tolerability, and improved outcomes for patients with PFIC- GlobeNewswire Inc

May 7, 2021

04:01PM EDT Albireo Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) GlobeNewswire Inc

May 6, 2021

09:04AM EDT Albireo Pharma Q1 EPS $(2.29) Misses $(1.77) Estimate, Sales $2.00M Miss $2.13M Estimate Benzinga

08:30AM EDT BylvayTM (odevixibat) commercial readiness on track for anticipated H2 21 launch in U.S. and EU GlobeNewswire Inc

07:49AM EDT The Daily Biotech Pulse: Merck's Keytruda Snags Another FDA Approval, Moderna Slips On Revenue Miss, Chemocentryx Adcom Benzinga

04:17AM EDT Earnings Scheduled For May 6, 2021 Benzinga

Apr 29, 2021

08:30AM EDT Albireo Pharma, Inc. (Nasdaq: ALBO), a clinical-stage orphan pediatric liver disease company developing novel bile acid modulators, today announced that management will host a conference call and live audio webcast at10:00 a.m. ET onMay 6, 2021, to provide a business update and review the companys financial results for the first quarter ended March 31, 2021. GlobeNewswire Inc

Apr 13, 2021

08:30AM EDT Appointment strengthens leadership team as the Company readies for potential global odevixibat launch and progresses multiple clinical development programs GlobeNewswire Inc

Apr 6, 2021

08:30AM EDT Albireo to Participate in the Needham 20th Annual Virtual GlobeNewswire Inc

Mar 25, 2021

08:34AM EDT Albireo Announces First Patient Dosed In 2 New Studies Benzinga

08:30AM EDT Dosed first patients in Phase 1 study with new product candidate A3907 GlobeNewswire Inc

Mar 1, 2021

09:53AM EST Piper Sandler Maintains Overweight on Albireo Pharma, Raises Price Target to $81 Benzinga

Feb 26, 2021

08:30AM EST Albireo Spotlights Global Patient Communities on Rare Disease Day GlobeNewswire Inc

Feb 25, 2021

08:41AM EST Albireo Pharma Q4 EPS $(1.30) Beats $(1.94) Estimate, Sales $2.72M Beat $2.34M Estimate Benzinga

08:08AM EST The Daily Biotech Pulse: Merck Goes Shopping, Decision Day For Sarepta, Pfizer, Moderna Unveil Vaccine Strategies For Coronavirus Variants Benzinga

08:00AM EST NDA and MAA for odevixibat accepted, on track for anticipated H2 21 launch GlobeNewswire Inc

04:03AM EST Earnings Scheduled For February 25, 2021 Benzinga

Feb 23, 2021

08:30AM EST Albireo to Participate in Cowen and H.C. Wainwright Global GlobeNewswire Inc

Feb 18, 2021

08:30AM EST Albireo Pharma, Inc. (Nasdaq: ALBO), a clinical-stage orphan pediatric liver disease company developing novel bile acid modulators, today announced that management will host a conference call and live audio webcast at10:00 a.m. ET onFebruary 25, 2021, to provide a business update and review the companys financial results for the fourth quarter and year ended December 31, 2020. GlobeNewswire Inc

Feb 17, 2021

04:30PM EST Albireo Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) GlobeNewswire Inc

Feb 11, 2021

08:40AM EST Albireo Pharma To Outline Commercial Plans For Odevixibat In Thursday Presentation At 11:30 a.m. EST Benzinga

08:30AM EST Company outlining large global rare cholestatic liver disease opportunity GlobeNewswire Inc

Jan 25, 2021

08:02AM EST Albireo Announces U.S. FDA Acceptance Of New Drug Application For Obenixibat Benzinga

08:00AM EST - Company receives FDA Priority Review with PDUFA date set for July 20, 2021 - GlobeNewswire Inc

Jan 22, 2021

08:30AM EST Albireo Recognizes International Alagille Syndrome Awareness Day 2021 GlobeNewswire Inc

Jan 14, 2021

04:30PM EST Albireo Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) GlobeNewswire Inc

Jan 7, 2021

08:30AM EST Albireo Pharma, Inc. (Nasdaq: ALBO), a clinical-stage rare liver disease company developing novel bile acid modulators, today announced that it will host a virtual Commercial Day for investors on February 11 from 11:30-1:00pm EST. GlobeNewswire Inc

Jan 6, 2021

04:30PM EST Albireo Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) GlobeNewswire Inc

Jan 5, 2021

08:30AM EST Albireo to Participate in H.C. Wainwright BioConnect and LifeSci GlobeNewswire Inc

Dec 17, 2020

08:02AM EST ALbireo Initiates Global Phase 3 Clinical Trial Of Odevixibat In Alagille Syndrome Benzinga

08:00AM EST - Study represents Albireos third global, Phase 3 trial in rare cholestatic liver diseases - GlobeNewswire Inc

Dec 11, 2020

04:30PM EST Albireo Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) GlobeNewswire Inc

Dec 8, 2020

04:30PM EST Albireo Reports Submission to FDA, EMA Product Approval Of Once-Daily Odevixibat For Progressive Familial Intrahepatic Cholestasis Benzinga

04:30PM EST - Dataon PFIC types 1, 2, 3 submitted to support use across a wide range of patients - GlobeNewswire Inc

Nov 13, 2020

08:10AM EST Albireo Pharma Highlights Presentation Of Data Showing 'Durable Response to Odevixibat in a Rare Pediatric Liver Disease' At AASLD Benzinga

08:05AM EST - PEDFIC 1meetsboth U.S. and EU primary and secondary endpoints with highlystatistically significant reductions in serum bile acids and pruritus- GlobeNewswire Inc

Nov 12, 2020

08:00AM EST Albireo to Participate in Jefferies and Piper Sandler Virtual GlobeNewswire Inc

Nov 5, 2020

07:56AM EST Albireo Pharma Q3 EPS $(1.96) Down From $(1.73) YoY Benzinga

07:30AM EST -Positive Phase 3 data forodevixibat in PFIC with filings on track for no later than early 2021 - GlobeNewswire Inc

Nov 2, 2020

08:13AM EST Albireo's Odevixibat PFIC Phase 3 Results Accepted For AASLD Late-Breakers Benzinga

08:00AM EST -Final PEDFIC 1 and interim PEDFIC 2 resultsacceptedat AASLDs The Liver Meeting 2020- GlobeNewswire Inc

Oct 23, 2020

09:23AM EDT Albireo Announces Presentations At NASPGHAN 2020 Annual Meeting Benzinga

09:20AM EDT -Research continues to show potential of odevixibat as first drug therapy for PFIC and in other rare liver diseases- GlobeNewswire Inc

Oct 20, 2020

09:04AM EDT Cramer Gives His Opinion On Cloudera, Barrick Gold And More Benzinga

Oct 5, 2020

08:30AM EDT Albireo Recognizes PFIC Awareness Day 2020 GlobeNewswire Inc

Oct 2, 2020

04:30PM EDT Albireo Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) GlobeNewswire Inc

Sep 20, 2020

10:09AM EDT Notable Insider Buys of the Past Week: Nikola, Transdigm And More Benzinga

Sep 15, 2020

11:28AM EDT Insider Buys Albireo Pharma's Shares Benzinga

Sep 9, 2020

09:17PM EDT Albireo Prices Public Offering of 4,000,000 Shares of Common Stock GlobeNewswire Inc

10:00AM EDT Albireo Pharma shares are trading lower after the company reported a common stock offering of 3 million shares. Benzinga

Sep 8, 2020

04:01PM EDT Albireo Reports 3M Share Offering Benzinga

04:01PM EDT Albireo Announces Proposed Public Offering of 3,000,000 Shares of GlobeNewswire Inc

02:33PM EDT Mid-Afternoon Market Update: Dow Falls 1.5%; Nikola Shares Surge Benzinga

01:38PM EDT Albiero Pharma Shares Move Higher; Jefferies Raises Price Target To $79, Upside Scenario To $107 Benzinga

12:31PM EDT HC Wainwright & Co. Maintains Buy on Albireo Pharma, Raises Price Target to $67 Benzinga

12:29PM EDT Needham Maintains Buy on Albireo Pharma, Raises Price Target to $68 Benzinga

12:00PM EDT Mid-Day Market Update: Nasdaq Tumbles Over 300 Points; Co-Diagnostics Shares Spike Higher Benzinga

10:22AM EDT Mid-Morning Market Update: Markets Open Lower; Grifols To Buy Geriatric Pharma Startup Alkahest Benzinga

10:02AM EDT Shares of Albireo Pharma Inc. (ALBO) surged over 70% on Tuesday morning after its liver disease drug meets primary endpoints in a late-stage study. RTTNews

06:44AM EDT Albireo Pharma Announces Positive Topline Results From PEDFIC 1 Trial RTTNews

06:37AM EDT Albireo Announces Phase 3 Trial Of Odevixibat Met Both Primary Endpoints Benzinga

06:30AM EDT -Highly statistically significant reductions in both pruritus and serum bile acids- GlobeNewswire Inc

Sep 7, 2020

10:14PM EDT Albireo To Announce Results From PEDFIC 1 Phase 3 Trial Of Odevixibat On September 8 RTTNews

05:00PM EDT Albireo to Announce Topline Results from Phase 3 Trial of Odevixibat for Treatment of PFIC on September 8, 2020 Benzinga

04:37PM EDT Albireo to Announce Topline Results from PEDFIC 1 Phase 3 Trial of GlobeNewswire Inc

Aug 19, 2020

10:40AM EDT Albireo Pharma shares are trading lower after the company announced on Tuesday its Phase 2 trial did not achieve proof-of-concept for other key NASH measures. Benzinga

08:36AM EDT 10 Biggest Price Target Changes For Wednesday Benzinga

06:50AM EDT HC Wainwright & Co. Maintains Buy on Albireo Pharma, Lowers Price Target to $50 Benzinga

Aug 18, 2020

04:46PM EDT Albireo Pharma Inc Says Trial Did Not Achieve Proof-of-Concept For Other Key Nash Measures; Says Trial Showed Unremarkable Results In Key Nash Measures Benzinga

04:43PM EDT Albireo Reports Topline Results From Phase 2 Trial Of Elobixibat In NAFLD/NASH; Company Discontinuing Further Development Benzinga

04:40PM EDT Achieved primary endpoint Unremarkable results in key NASH measures Company discontinuing further development GlobeNewswire Inc

Aug 6, 2020

08:27AM EDT Albireo Pharma Q2 EPS $(1.38) Beats $(1.69) Estimate, Sales $1.91M Beat $1.28M Estimate Benzinga

07:30AM EDT Completed last patient visits in Phase 3 PFIC and Phase 2 NASH TrialsEnrolled first biliary atresia patients in second odevixibat pivotal study Completed two financing transactions to secure cash into beginning of 2022 Management to host conference call and webcast today at 10:00 a.m. ET GlobeNewswire Inc

Jul 31, 2020

12:55PM EDT Piper Sandler Initiates Coverage On Albireo Pharma with Overweight Rating, Announces Price Target of $45 Benzinga

Jul 30, 2020

08:00AM EDT Conference call and webcast to be held at 10:00 a.m. ET GlobeNewswire Inc

Jul 20, 2020

08:03AM EDT Albireo Pharma Announces the Launch of an Expanded Access Program for its Odevixibat Benzinga

08:00AM EDT Albireo Launches Expanded Access Program for Odevixibat for GlobeNewswire Inc

Jul 16, 2020

11:15AM EDT HC Wainwright & Co. Maintains Buy on Albireo Pharma, Raises Price Target to $64 Benzinga

Jul 14, 2020

07:39AM EDT Albireo Pharma Enrolls First Patient In Phase 3 Clinical Trial Of Odevixibat In Biliary Atresia RTTNews

07:32AM EDT Albireo Enrolls First Patient In Phase 3 Clinical Trial Of Odevixibat In Biliary Atresia Benzinga

07:30AM EDT Albireo Enrolls First Patient in Phase 3 Clinical Trial of GlobeNewswire Inc